August is not turning out to be a quiet month for Daiichi Sankyo Co., Ltd. and AstraZeneca PLC, where the anti-HER2 antibody-drug conjugate Enhertu nabbed its second pathbreaking approval in less than two weeks.
Ophthalmic specialty company Novaliq also stood out, with two recent new drug applications (one partnered with Bausch + Lomb Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?